SNRIs: blood pressure, discontinuation, serotonin syndrome and suicidality

What dual reuptake inhibition adds

SNRIs, including venlafaxine, desvenlafaxine, duloxetine and levomilnacipran, increase both serotonin and norepinephrine activity. They are used for depression and, depending on the drug, for anxiety and chronic pain conditions. Their toxicity is closer to SSRIs than to tricyclic antidepressants. Nausea is the most common early problem, usually in the first couple of weeks.

The norepinephrine component explains why SNRIs differ from SSRIs in exam questions. It can raise blood pressure and heart rate and contribute to sweating and urinary hesitation. When a question gives a patient with poorly controlled hypertension starting an antidepressant, consider whether the SNRI effect on blood pressure is the point being tested.

Blood pressure and other monitoring

Venlafaxine produces a modest, dose-related rise in diastolic pressure, and duloxetine a modest rise in systolic and diastolic pressure. The duloxetine label advises measuring blood pressure before starting and periodically during treatment. Report sustained elevation, headache or palpitations. Duloxetine can also cause orthostatic hypotension, falls and fainting, so check lying and standing readings in older adults.

Duloxetine carries a hepatotoxicity warning and is avoided with substantial alcohol use or chronic liver disease; report jaundice, dark urine or right upper abdominal pain. Hyponatraemia can occur, particularly in older adults, presenting as headache, confusion or unsteadiness. Urinary hesitation or retention and angle-closure glaucoma in people with narrow angles are further listed warnings.

For practical monitoring, record a baseline blood pressure and heart rate before the first dose and repeat them after dose increases, using the same arm and position each time. Compare the trend rather than a single reading. A patient who already has hypertension needs particular attention, and the prescriber may adjust antihypertensive treatment or reconsider the antidepressant choice.

Serotonin syndrome, bleeding and interactions

Serotonin syndrome can occur alone but is more likely with other serotonergic drugs such as triptans, tramadol, other antidepressants or St John's wort. Watch for agitation, tremor, sweating, fever, fast heart rate and muscle twitching. Combining an SNRI with an MAOI is contraindicated, as is starting duloxetine within 14 days of stopping an MAOI antidepressant.

SNRIs can increase bleeding risk, more so with aspirin, other NSAIDs, antiplatelets or anticoagulants. Ask about nosebleeds, easy bruising and dark stools. Teach patients to check with the pharmacist before buying cough, cold, pain or herbal remedies. Duloxetine capsules are swallowed whole, not crushed, chewed or opened, which matters for patients with swallowing difficulty.

Discontinuation symptoms and suicidality

Stopping an SNRI suddenly often causes discontinuation symptoms such as dizziness, irritability, anxiety, nausea, headache, confusion and tiredness. The dose is reduced gradually under the prescriber's plan. Teach patients not to stop on their own, to keep enough supply, and to report symptoms after missed doses, which can mimic relapse.

Antidepressants carry a boxed warning about increased suicidal thoughts and actions in children, adolescents and young adults under 24, especially early in treatment and after dose changes. Ask directly about suicidal thinking, involve family where appropriate, and report new agitation, worsening mood or unusual behaviour. Screen for bipolar history, since antidepressants can trigger mania.

Worked exam-style scenario

Imagine a hypothetical 20-year-old who started venlafaxine three weeks ago and now reports feeling restless, sleeping poorly and having thoughts that life is not worth living. Options include reassuring that the drug takes weeks to work, advising them to stop the medicine, increasing fluids, or asking directly about suicidal intent and escalating promptly.

Asking directly and escalating is the strongest answer because early treatment in a young adult is a recognised higher-risk window. Reassurance alone misses the danger. Advising abrupt stopping adds discontinuation symptoms without addressing safety. In a second version, an older adult reports a blood pressure well above baseline; reporting the reading is preferred over waiting for the next appointment.

Sources and further reading

DailyMed: CYMBALTA (duloxetine) prescribing information. Blood pressure monitoring, hepatotoxicity, orthostasis, serotonin syndrome, bleeding, hyponatraemia, urinary retention, MAOI contraindication and gradual tapering.

MedlinePlus: Venlafaxine. Suicidality boxed warning under age 24 and withdrawal symptoms after sudden stopping.

MSD Manual Professional: Drug treatment of depression. SNRI mechanism, dose-related blood pressure increases for venlafaxine and duloxetine, nausea, bleeding risk and discontinuation symptoms.